Cargando…

Identification of a Gene Panel Predictive of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy Employing Transcriptomic and Functional Validation

Triple-negative breast cancer (TNBC) patients exhibiting pathological complete response (pCR) have better clinical outcomes compared to those with residual disease (RD). Therefore, robust biomarkers that can predict pCR may help with triage and resource prioritization in patients with TNBC. Herein,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vishnubalaji, Radhakrishnan, Abdel-Razeq, Hikmat, Gehani, Salahddin, Albagha, Omar M. E., Alajez, Nehad M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506546/ https://www.ncbi.nlm.nih.gov/pubmed/36142814 http://dx.doi.org/10.3390/ijms231810901

Ejemplares similares

Single-cell long noncoding RNA (lncRNA) transcriptome implicates MALAT1 in triple-negative breast cancer (TNBC) resistance to neoadjuvant chemotherapy
por: Shaath, Hibah, et al.
Publicado: (2021)

Transcriptional landscape associated with TNBC resistance to neoadjuvant chemotherapy revealed by single-cell RNA-seq
por: Vishnubalaji, Radhakrishnan, et al.
Publicado: (2021)

Epigenetic regulation of triple negative breast cancer (TNBC) by TGF-β signaling
por: Vishnubalaji, Radhakrishnan, et al.
Publicado: (2021)

Long non-coding RNA AC099850.4 correlates with advanced disease state and predicts worse prognosis in triple-negative breast cancer
por: Vishnubalaji, Radhakrishnan, et al.
Publicado: (2023)

LncRNA-Based Classification of Triple Negative Breast Cancer Revealed Inherent Tumor Heterogeneity and Vulnerabilities
por: Vishnubalaji, Radhakrishnan, et al.
Publicado: (2022)

Transcriptional alterations of protein coding and noncoding RNAs in triple negative breast cancer in response to DNA methyltransferases inhibition
por: Elango, Ramesh, et al.
Publicado: (2021)

Single-Cell Transcriptome Analysis Revealed Heterogeneity and Identified Novel Therapeutic Targets for Breast Cancer Subtypes
por: Vishnubalaji, Radhakrishnan, et al.
Publicado: (2023)

Transcriptome profiling and network enrichment analyses identify subtype-specific therapeutic gene targets for breast cancer and their microRNA regulatory networks
por: Elango, Ramesh, et al.
Publicado: (2023)

Single-Cell Transcriptome Analysis Highlights a Role for Neutrophils and Inflammatory Macrophages in the Pathogenesis of Severe COVID-19
por: Shaath, Hibah, et al.
Publicado: (2020)

Integrated Transcriptome and Pathway Analyses Revealed Multiple Activated Pathways in Breast Cancer
por: Vishnubalaji, Radhakrishnan, et al.
Publicado: (2019)

Protein Coding and Long Noncoding RNA (lncRNA) Transcriptional Landscape in SARS-CoV-2 Infected Bronchial Epithelial Cells Highlight a Role for Interferon and Inflammatory Response
por: Vishnubalaji, Radhakrishnan, et al.
Publicado: (2020)

Molecular Classification of Breast Cancer Utilizing Long Non-Coding RNA (lncRNA) Transcriptomes Identifies Novel Diagnostic lncRNA Panel for Triple-Negative Breast Cancer
por: Shaath, Hibah, et al.
Publicado: (2021)

Long non-coding RNA (lncRNA) transcriptional landscape in breast cancer identifies LINC01614 as non-favorable prognostic biomarker regulated by TGFβ and focal adhesion kinase (FAK) signaling
por: Vishnubalaji, Radhakrishnan, et al.
Publicado: (2019)

Molecular subtyping and functional validation of TTK, TPX2, UBE2C, and LRP8 in sensitivity of TNBC to paclitaxel
por: Elango, Ramesh, et al.
Publicado: (2021)

Treatment Strategies for Residual Disease following Neoadjuvant Chemotherapy in Patients with Early-Stage Breast Cancer
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2022)

Current neoadjuvant treatment options for HER2-positive breast cancer
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2011)

Deciding to Remove or Leave a Peritoneal Loose Body: A Case Report and Review of Literature
por: Obaid, Munzir, et al.
Publicado: (2018)

Transcriptome Meta-Analysis of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy
por: Zhang, Wei, et al.
Publicado: (2023)

Gonadotropin-releasing hormone agonists during chemotherapy for ovarian function and fertility preservation for patients with early-stage breast cancer
por: Abdel-Razeq, Hikmat
Publicado: (2019)

In vitro differentiation of human skin-derived multipotent stromal cells into putative endothelial-like cells
por: Vishnubalaji, Radhakrishnan, et al.
Publicado: (2012)

CDH1 and IL1-beta expression dictates FAK and MAPKK-dependent cross-talk between cancer cells and human mesenchymal stem cells
por: Al-toub, Mashael, et al.
Publicado: (2015)

Therapeutic targeting of the TPX2/TTK network in colorectal cancer
por: Shaath, Hibah, et al.
Publicado: (2023)

MicroRNA-320 suppresses colorectal cancer by targeting SOX4, FOXM1, and FOXQ1
por: Vishnubalaji, Radhakrishnan, et al.
Publicado: (2016)

Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
por: Abdel-Razeq, Hikmat
Publicado: (2016)

Angiogenic Potential of Human Neonatal Foreskin Stromal Cells in the Chick Embryo Chorioallantoic Membrane Model
por: Vishnubalaji, Radhakrishnan, et al.
Publicado: (2015)

Bone morphogenetic protein 2 (BMP2) induces growth suppression and enhances chemosensitivity of human colon cancer cells
por: Vishnubalaji, Radhakrishnan, et al.
Publicado: (2016)

CXCR7 signaling promotes breast cancer survival in response to mesenchymal stromal stem cell-derived factors
por: Al-toub, Mashael, et al.
Publicado: (2019)

Comprehensive Transcriptome and Pathway Analyses Revealed Central Role for Fascin in Promoting Triple-Negative Breast Cancer Progression
por: Barnawi, Rayanah, et al.
Publicado: (2021)

Molecular profiling of ALDH1(+) colorectal cancer stem cells reveals preferential activation of MAPK, FAK, and oxidative stress pro-survival signalling pathways
por: Vishnubalaji, Radhakrishnan, et al.
Publicado: (2018)

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study
por: Shao, Zhiying, et al.
Publicado: (2016)

Patterns and Prevalence of BRCA1 and BRCA2 Germline Mutations Among Patients with Triple-Negative Breast Cancer: Regional Perspectives
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2021)

Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2022)

Treatment options for patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer: maintaining cyclin-dependent kinase 4/6 inhibitors beyond progression
por: Horani, Malek, et al.
Publicado: (2023)

Enhanced Efficacy of 5-Fluorouracil in Combination with a Dual Histone Deacetylase and Phosphatidylinositide 3-Kinase Inhibitor (CUDC-907) in Colorectal Cancer Cells
por: Hamam, Rimi, et al.
Publicado: (2017)

A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors
por: Pérez-Pena, Javier, et al.
Publicado: (2019)

The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer
por: Castrellon, Aurelio Bartolome, et al.
Publicado: (2017)

Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
por: Ghallab, Ahmed
Publicado: (2020)

Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer
por: Ding, Feng, et al.
Publicado: (2022)

The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: Johnson, Kai Conrad Cecil, et al.
Publicado: (2023)

Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Omar, Mohamed, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gjlvsp04dve8o5epge11rg8l6r